Hanemaaijer Susan, Sodihardjo Fong, Horikx Annemieke, Wensing Michel, De Smet Peter A G M, Bouvy Marcel L, Teichert Martina
Royal Dutch Pharmacists Association (KNMP), 2514JL, The Hague, The Netherlands.
Division of Pharmacoepidemiology and Clinical Pharmacology, Faculty of Science, Utrecht Institute of Sciences, Utrecht University, PO Box 80082, 3508 TB, Utrecht, The Netherlands.
Int J Clin Pharm. 2015 Dec;37(6):1128-35. doi: 10.1007/s11096-015-0174-4. Epub 2015 Aug 5.
Non-vitamin K oral anticoagulants (NOACs) became available in the Netherlands in 2008, providing another antithrombotic treatment besides vitamin K antagonists (VKAs) and antiplatelet agents (APAs).
To describe the patterns of antithrombotic drug use between 2008 and 2013 by examination of dispensing data form community pharmacies in the Netherlands; to determine the concomitant use of NOACs with VKAs and APAs and switching between the drug classes; and to compare adherence to NOACs with adherence to APAs.
An observational retrospective study was conducted using routinely collected dispensing data from Dutch community pharmacies.
For each calendar year, the numbers of NOAC, VKA, and APA users were calculated. Adherence was determined for NOACs and APAs by the percentage of days covered by medication (PDC). Information on the prescribed daily dose of VKAs was unavailable.
Comparison of age, sex, and co-medications of users of the three drug classes; concomitant use of different antithrombotic drug classes and switching between these in each year; and mean PDC and percentages of all users with a PDC above 80 %.
NOAC use increased during the study period to 29,687 users in 2013. In that year there were 484,024 VKA users and 1313,032 APA users. Compared with users of VKAs, NOAC users were slightly younger and more frequently used antiarrhythmic drugs and beta blockers as co-medications. Substantial numbers of patients were dispensed potentially harmful combinations in 2013: 820 subjects were dispensed NOACs together with VKAs, and 684 subjects were dispensed NOACs, VKAs, and APAs concomitantly. Mean adherence to NOACs was 84.2 % compared with 87.3 % to APA. One in four NOAC users had a PDC lower than 80 % compared with one in five APA users.
Our findings show increasing use of NOACs by outpatients. The number of patients taking potentially harmful combinations of antithrombotic drugs was substantial. Adherence to NOACs in daily practice may be suboptimal to prevent thrombotic events.
非维生素K口服抗凝药(NOACs)于2008年在荷兰上市,成为除维生素K拮抗剂(VKAs)和抗血小板药物(APAs)之外的另一种抗血栓治疗药物。
通过分析荷兰社区药房的配药数据,描述2008年至2013年期间抗血栓药物的使用模式;确定NOACs与VKAs和APAs的联合使用情况以及药物类别之间的转换情况;并比较NOACs与APAs的依从性。
采用荷兰社区药房常规收集的配药数据进行一项观察性回顾性研究。
计算每个日历年中使用NOACs、VKAs和APAs的人数。通过药物覆盖天数百分比(PDC)确定NOACs和APAs的依从性。无法获取VKAs规定日剂量的信息。
比较三类药物使用者的年龄、性别和合并用药情况;每年不同抗血栓药物类别的联合使用情况以及它们之间的转换情况;平均PDC以及PDC高于80%的所有使用者的百分比。
在研究期间,NOACs的使用量增加,2013年达到29,687名使用者。同年,有484,024名VKA使用者和1313,032名APA使用者。与VKA使用者相比,NOAC使用者年龄稍小,更频繁地将抗心律失常药物和β受体阻滞剂作为合并用药。2013年有大量患者被配到可能有害的组合药物:820名受试者同时使用了NOACs和VKAs,684名受试者同时使用了NOACs、VKAs和APAs。NOACs的平均依从性为84.2%,而APAs为87.3%。四分之一的NOAC使用者PDC低于80%,而五分之一的APA使用者PDC低于80%。
我们的研究结果表明门诊患者对NOACs的使用在增加。服用抗血栓药物潜在有害组合的患者数量可观。在日常实践中,为预防血栓形成事件,对NOACs的依从性可能欠佳。